Drug Profile
CVT 2
Latest Information Update: 30 May 2001
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Class Anti-ischaemics; Antihyperlipidaemics
- Mechanism of Action Complement C5a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Myocardial infarction; Renal failure
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 30 Jun 1998 No-Development-Reported for Atherosclerosis in USA (Unknown route)
- 30 Jun 1998 No-Development-Reported for Myocardial infarction in USA (Unknown route)